Description: NSC 207895 suppresses MDMX with IC50 of 2.5 μM, leading to enhanced p53 stabilization/activation and DNA damage, and also regulates MDM2, an E3 ligase. NSC 207895 is a benzofuroxan derivative and is less toxic. NSC 207895 decreases the activity of MDMX promoter and subsequently decreases both the mRNA and protein levels of MDMX in MCF-7 cells. This inhibition of MDMX is accompanied with the activation of p53.
Reference: Mol Cancer Ther. 2011 Jan;10(1):69-79.
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19413412
| NSC-207895 decreases both the MDMX mRNA and protein in MCF-7 cells. NSC-207895 induces expression of p53 as well as well-characterized p53-target gene, p21 and MDM2, in a dose-dependent manner in MCF-7 cells. NSC-207895 extends the half-life of p53 from 20 to 30 minutes to more than 3 hours as revealed by cycloheximide chase assays in MCF-7 cells. | |
|---|---|
| In vivo | |
| Formulation | |
| Dosages | |
| Administration | |
| Reference | [1] Wang H, et al. Mol Cancer Ther, 2011, 10(1), 69-79. |
